Track Fortress Biotech, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Fortress Biotech, Inc. FBIO Open Fortress Biotech, Inc. in new tab

2.80 USD
P/E
0.77
EPS
3.23
P/B
1.56
ROE
-108.74
Beta
1.16
Target Price
11.00 USD
Fortress Biotech, Inc. logo

Fortress Biotech, Inc.

🧾 Earnings Recap – Q3 2025

Journey Medical delivered robust performance in Q3 2025, achieving 21% year-over-year revenue growth, driven primarily by the strong uptake of its new oral treatment, EMROSI.

  • EMROSI contributed $4.9 million, showing a 75% revenue increase compared to Q2, with total prescriptions growing 146%.
  • Despite a 16% year-over-year decline in revenue for legacy products due to Accutane generic competition, overall product revenues grew by more than 16% year-over-year.
  • Operating expenses rose only 9%, highlighting effective expense management linked to EMROSI's launch and potential for sustainable EBITDA positivity in Q4.
  • Over 2,700 unique prescribers have adopted EMROSI, a 50% increase since the last earnings call, indicating strong market acceptance and growth potential.
  • The company has secured access for EMROSI across over 100 million of the 187 million commercial lives, with further GPO contracting expected.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 13, 2026
P/E0.77
EPS3.23
Book Value1.59
Price to Book1.56
Debt/Equity108.09
% Insiders22.791%
Growth
Revenue Growth0.06%
Estimates
Forward P/E-1.41
Forward EPS-1.76
Target Mean Price11.00

DCF Valuation

Tweak assumptions to recompute fair value for Fortress Biotech, Inc. (FBIO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Fortress Biotech, Inc. Logo Fortress Biotech, Inc. Analysis (FBIO)

United States Health Care Official Website Stock

Is Fortress Biotech, Inc. a good investment? Fortress Biotech, Inc. (FBIO) is currently trading at 2.80 USD. Market analysts have a consensus price target of 11.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 0.77. This relatively low multiple may signal that Fortress Biotech, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Fortress Biotech, Inc. is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is -1.76.

Investor FAQ

Does Fortress Biotech, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Fortress Biotech, Inc.?

Fortress Biotech, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of 3.23.

Company Profile

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Exchange Ticker
NCM (Australia) FBIO

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Oct. 10, 2023 0.070000
Oct. 10, 2023 0.070000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion